First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC

Παρόμοια τεκμήρια

• Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
  ανά: Y. Uehara, κ.ά.
  Έκδοση: (2024-09-01)
• Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
  ανά: Liam, Chong-Kin
  Έκδοση: (2017)
• Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives
  ανά: Ricciuti, Biagio
  Έκδοση: (2019)
• Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
  ανά: Denis, Marc G, κ.ά.
  Έκδοση: (2020)
• Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
  ανά: Ohe, Yuichiro, κ.ά.
  Έκδοση: (2018)